Clinical Trial

Vebreltinib Plus Chemotherapy as First-line Treatment for MET-overexpressing NSCLC

Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
To explore the efficacy and safety of vebreltinib plus platinum-doublet chemotherapy as first-line therapy in patients with driver gene-negative, locally advanced or metastatic non-small cell lung cancer (NSCLC) with MET overexpression.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-04-16.
Trial Details
NCT Number NCT07549061
Lead Sponsor Shanghai Chest Hospital
Conditions Lung Neoplasms
Enrollment 19 participants
Start Date 2026-03-30
Primary Completion 2028-05-30 (estimated)
Study Completion 2028-12-30 (estimated)
Updated on ClinicalTrials.gov 2026-04-29